Mergers & Acquisitions

Found 18,659 articles

• SmilePartners-USA Completes Multiple Add-On Acquisitions

  1/7/2021

  SmilePartners-USA, a portfolio company of Silver Oak Services Partners, LLC, announced the acquisition of PEDIA, a leading provider of general dentistry and oral surgery services in Chicago, IL, operating 14 locations throughout the Chicago metropolitan area.

• Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs

  1/7/2021

  Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. ("Kleo") that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab

• MilliporeSigma Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics

  1/7/2021

  Adds to MilliporeSigma's lipid manufacturing expertise, providing an integrated offering across mRNA value chain

• 

  Top Life Sciences Startups to Watch in 2021

  1/6/2021

  BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
• 

  Top 2020 Biopharma M&A Deals

  1/6/2021

  BioSpace highlights a number of the key M&A deals struck over the past 12 months.

• Holy Name Medical Center in Teaneck, New Jersey Acquires Sensus Healthcare’s Low-dose Radiation Therapy System to Treat Pneumonia in COVID-19 Patients

  1/6/2021

  Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced Holy Name Medical Center in Teaneck, New Jersey has acquired a Sensus low-dose radiation therapy system for the treatment of pneumonia in COVID-19 patients.

• BioMed Realty Acquires Flagship Property in Boston’s Seaport District

  1/6/2021

  601 Congress Street further builds on developer's premier life science real estate portfolio in Boston/Cambridge

• SK Capital Announces Agreement to Acquire Catalent’s Blow-Fill-Seal Sterile CDMO Business

  1/6/2021

  SK Capital Partners LP, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, announced that funds it advises have signed a definitive agreement to acquire the Blow-Fill-Seal Sterile Contract Development and Manufacturing Business from Catalent Pharma Solutions, LLC.

• Genesis Drug Discovery and Development Expands Its Presence in the Clinical Space by Acquiring STATKING Clinical Services

  1/6/2021

  Genesis Biotechnology Group® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD3) announced today that it has acquired the Cincinnati-based CRO STATKING Clinical Services.

• Bioclinica Acquires Saliency to Accelerate Digital Diagnostic Development

  1/6/2021

  New AI integration dramatically speeds medical image interpretation and model creation within Bioclinica's imaging platform

• Sartorius Stedim Biotech to acquire Novasep's chromatography process equipment division

  1/6/2021

  Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, announced it has entered into an agreement to acquire the chromatography process equipment division of Novasep.

• Sartorius to acquire Novasep's chromatography process equipment division

  1/6/2021

  The life science company Sartorius announced it has entered into an agreement through its subgroup Sartorius Stedim Biotech to acquire the chromatography process equipment division of Novasep.

• Radius Health, Inc. Announces Acquisition of Orphan Disease Program

  1/6/2021

  RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases

• Wiley Announces the Acquisition of Hindawi

  1/5/2021

  A Global Leader in Research and Education Accelerates its Strategy to Power the World’s Knowledge Ecosystem by Acquiring a Fast-Growing Innovator in Open Access

• Exact Sciences Completes Acquisition of Thrive Earlier Detection, Creating a Leader in Blood-Based, Multi-Cancer Screening

  1/5/2021

  Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive")

• Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million

  1/5/2021

  – Transaction Accelerates Hologic’s Entry into Oncology Growth Market, Provides New Lab Capabilities – – Hologic’s Commercial Resources, Expertise in Molecular Automation Expected to Boost Biotheranostics Growth –

• Adamas Completes Acquisition of OSMOLEX ER®Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition

  1/5/2021

  Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of the settlement of patent litigation with Osmotica Pharmaceutical US LLC, a subsidiary of Osmotica Pharmaceuticals plc and completes the acquisition of the global rights to OSMOLEX ER®. As previously disclosed, the amended Royalty-

• Blue Earth Diagnostics Acquires Exclusive, Worldwide Rights to Therapeutic Applications of Scintomics’ Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) Technology for Prostate Cancer

  1/5/2021

  Expanded oncology portfolio includes comprehensive prostate cancer franchise to address patient management across the care continuum

• Diakard makes key acquisition in the creation of a global network of Diakard Centers of Excellence

  1/5/2021

   DIAKARD, INC. a global provider of innovative diabetes treatments and solutions, today announced its acquisition of Pfützner Science and Health Institute, GmbH (PSHI), an internationally recognized developer and provider of therapeutics, diagnostics and clinical care in diabetes and related conditions. PSHI spec

• NAMSA® Acquires Syntactx to Enhance End-to-End CRO Development Solutions, Expanding Medical Device Clinical Research Capabilities and Expertise

  1/5/2021

  NAMSA ® Acquires Syntactx to Enhance End-to-End CRO Development Solutions, Expanding Medical Device Clinical Research Capabilities and Expertise TOLEDO, Ohio & NEW YORK--( BUSINESS WIRE )-- NAMSA , the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of New York-based CRO, Syntactx . This acquisition follows independent healthcare investment fir